Legend Biotech says Phase 1 LB2102 CAR-T posts 28.6% response rate in relapsed solid tumors at higher doses

Legend Biotech

Legend Biotech

LEGN

0.00
  • Legend Biotech presented first-in-human Phase 1 data for LB2102 in relapsed or refractory SCLC or LCNEC at ASCO 2026.
  • Results showed early signs of tumor shrinkage in a hard-to-treat, heavily pretreated population, with some responses lasting for months.
  • Safety looked manageable, with no dose-limiting toxicities or treatment-related deaths reported, supporting continued development in solid tumors.
  • Separate CARVYKTI analyses were also presented at ASCO 2026, reinforcing durable benefit in multiple myeloma with no new safety signal highlighted.
  • The LB2102 update supports a strategy to expand beyond blood cancers, while Novartis holds worldwide rights for most development and commercialization.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Legend Biotech Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606011000PRIMZONEFULLFEED9729391) on June 01, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.